Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: 3-Month Data From a Randomized Phase 3 Trial.

Asrani S, Robin AL, Serle JB, Lewis RA, Usner DW, Kopczynski CC, Heah T; Mercury-1 Study Group.

Am J Ophthalmol. 2019 Jun 20. pii: S0002-9394(19)30284-3. doi: 10.1016/j.ajo.2019.06.016. [Epub ahead of print]

2.

Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.

Khouri AS, Serle JB, Bacharach J, Usner DW, Lewis RA, Braswell P, Kopczynski CC, Heah T; Rocket-4 Study Group.

Am J Ophthalmol. 2019 Aug;204:97-104. doi: 10.1016/j.ajo.2019.03.002. Epub 2019 Mar 9.

3.

Long-term Safety and Ocular Hypotensive Efficacy Evaluation of Netarsudil Ophthalmic Solution: Rho Kinase Elevated IOP Treatment Trial (ROCKET-2).

Kahook MY, Serle JB, Mah FS, Kim T, Raizman MB, Heah T, Ramirez-Davis N, Kopczynski CC, Usner DW, Novack GD; ROCKET-2 Study Group.

Am J Ophthalmol. 2019 Apr;200:130-137. doi: 10.1016/j.ajo.2019.01.003. Epub 2019 Jan 15.

4.

Netarsudil ophthalmic solution 0.02% for the treatment of patients with open-angle glaucoma or ocular hypertension.

Kopczynski CC, Heah T.

Drugs Today (Barc). 2018 Aug;54(8):467-478. doi: 10.1358/dot.2018.54.8.2849627. Review.

PMID:
30209441
5.

Consensus recommendations for trabecular meshwork cell isolation, characterization and culture.

Keller KE, Bhattacharya SK, Borrás T, Brunner TM, Chansangpetch S, Clark AF, Dismuke WM, Du Y, Elliott MH, Ethier CR, Faralli JA, Freddo TF, Fuchshofer R, Giovingo M, Gong H, Gonzalez P, Huang A, Johnstone MA, Kaufman PL, Kelley MJ, Knepper PA, Kopczynski CC, Kuchtey JG, Kuchtey RW, Kuehn MH, Lieberman RL, Lin SC, Liton P, Liu Y, Lütjen-Drecoll E, Mao W, Masis-Solano M, McDonnell F, McDowell CM, Overby DR, Pattabiraman PP, Raghunathan VK, Rao PV, Rhee DJ, Chowdhury UR, Russell P, Samples JR, Schwartz D, Stubbs EB, Tamm ER, Tan JC, Toris CB, Torrejon KY, Vranka JA, Wirtz MK, Yorio T, Zhang J, Zode GS, Fautsch MP, Peters DM, Acott TS, Stamer WD.

Exp Eye Res. 2018 Jun;171:164-173. doi: 10.1016/j.exer.2018.03.001. Epub 2018 Mar 9. Review.

6.

The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans.

Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ.

J Ocul Pharmacol Ther. 2018 Jun;34(5):380-386. doi: 10.1089/jop.2017.0138. Epub 2018 Feb 22.

7.

Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).

Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC; ROCKET-1 and ROCKET-2 Study Groups.

Am J Ophthalmol. 2018 Feb;186:116-127. doi: 10.1016/j.ajo.2017.11.019. Epub 2017 Dec 1.

8.

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.

Lin CW, Sherman B, Moore LA, Laethem CL, Lu DW, Pattabiraman PP, Rao PV, deLong MA, Kopczynski CC.

J Ocul Pharmacol Ther. 2018 Jan/Feb;34(1-2):40-51. doi: 10.1089/jop.2017.0023. Epub 2017 Jun 13.

9.

Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms.

Ren R, Li G, Le TD, Kopczynski C, Stamer WD, Gong H.

Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6197-6209. doi: 10.1167/iovs.16-20189.

10.

Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Rao PV, Pattabiraman PP, Kopczynski C.

Exp Eye Res. 2017 May;158:23-32. doi: 10.1016/j.exer.2016.08.023. Epub 2016 Sep 1. Review.

11.

Visualization of conventional outflow tissue responses to netarsudil in living mouse eyes.

Li G, Mukherjee D, Navarro I, Ashpole NE, Sherwood JM, Chang J, Overby DR, Yuan F, Gonzalez P, Kopczynski CC, Farsiu S, Stamer WD.

Eur J Pharmacol. 2016 Sep 15;787:20-31. doi: 10.1016/j.ejphar.2016.04.002. Epub 2016 Apr 13.

12.

Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.

Sturdivant JM, Royalty SM, Lin CW, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA.

Bioorg Med Chem Lett. 2016 May 15;26(10):2475-2480. doi: 10.1016/j.bmcl.2016.03.104. Epub 2016 Apr 1.

PMID:
27072905
13.

Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.

Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD; PG324-CS201 Study Group.

Br J Ophthalmol. 2016 Mar;100(3):339-44. doi: 10.1136/bjophthalmol-2015-306778. Epub 2015 Jul 24. Erratum in: Br J Ophthalmol. 2016 Jul;100(7):1016.

PMID:
26209587
14.

Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits.

Kiel JW, Kopczynski CC.

J Ocul Pharmacol Ther. 2015 Apr;31(3):146-51. doi: 10.1089/jop.2014.0146. Epub 2015 Mar 10.

15.

Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers.

Levy B, Ramirez N, Novack GD, Kopczynski C.

Am J Ophthalmol. 2015 May;159(5):980-5.e1. doi: 10.1016/j.ajo.2015.01.026. Epub 2015 Jan 28.

PMID:
25637177
16.

Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes.

Wang RF, Williamson JE, Kopczynski C, Serle JB.

J Glaucoma. 2015 Jan;24(1):51-4. doi: 10.1097/IJG.0b013e3182952213.

PMID:
25535688
17.

Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.

Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD; AR-13324-CS202 Study Group.

Ophthalmology. 2015 Feb;122(2):302-7. doi: 10.1016/j.ophtha.2014.08.022. Epub 2014 Sep 27.

PMID:
25270273
18.

Emerging trabecular outflow drugs.

Kopczynski CC, Epstein DL.

J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):85-7. doi: 10.1089/jop.2013.0197. Epub 2013 Dec 4. No abstract available.

19.

Ocular hypotensive efficacy, safety and systemic absorption of AR-12286 ophthalmic solution in normal volunteers.

Kopczynski C, Novack GD, Swearingen D, van Haarlem T.

Br J Ophthalmol. 2013 May;97(5):567-72. doi: 10.1136/bjophthalmol-2012-302466. Epub 2013 Feb 22.

PMID:
23435190
20.

Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.

Williams RD, Novack GD, van Haarlem T, Kopczynski C; AR-12286 Phase 2A Study Group.

Am J Ophthalmol. 2011 Nov;152(5):834-41.e1. doi: 10.1016/j.ajo.2011.04.012. Epub 2011 Jul 27.

PMID:
21794845
21.

Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene.

Edgar KA, Belvin M, Parks AL, Whittaker K, Mahoney MB, Nicoll M, Park CC, Winter CG, Chen F, Lickteig K, Ahmad F, Esengil H, Lorenzi MV, Norton A, Rupnow BA, Shayesteh L, Tabios M, Young LM, Carroll PM, Kopczynski C, Plowman GD, Friedman LS, Francis-Lang HL.

Genetics. 2005 May;170(1):161-71. Epub 2005 Mar 2.

22.

A complementary transposon tool kit for Drosophila melanogaster using P and piggyBac.

Thibault ST, Singer MA, Miyazaki WY, Milash B, Dompe NA, Singh CM, Buchholz R, Demsky M, Fawcett R, Francis-Lang HL, Ryner L, Cheung LM, Chong A, Erickson C, Fisher WW, Greer K, Hartouni SR, Howie E, Jakkula L, Joo D, Killpack K, Laufer A, Mazzotta J, Smith RD, Stevens LM, Stuber C, Tan LR, Ventura R, Woo A, Zakrajsek I, Zhao L, Chen F, Swimmer C, Kopczynski C, Duyk G, Winberg ML, Margolis J.

Nat Genet. 2004 Mar;36(3):283-7. Epub 2004 Feb 22.

23.

Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.

Parks AL, Cook KR, Belvin M, Dompe NA, Fawcett R, Huppert K, Tan LR, Winter CG, Bogart KP, Deal JE, Deal-Herr ME, Grant D, Marcinko M, Miyazaki WY, Robertson S, Shaw KJ, Tabios M, Vysotskaia V, Zhao L, Andrade RS, Edgar KA, Howie E, Killpack K, Milash B, Norton A, Thao D, Whittaker K, Winner MA, Friedman L, Margolis J, Singer MA, Kopczynski C, Curtis D, Kaufman TC, Plowman GD, Duyk G, Francis-Lang HL.

Nat Genet. 2004 Mar;36(3):288-92. Epub 2004 Feb 22.

24.

A genome-wide analysis of immune responses in Drosophila.

Irving P, Troxler L, Heuer TS, Belvin M, Kopczynski C, Reichhart JM, Hoffmann JA, Hetru C.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15119-24. Epub 2001 Dec 11.

25.

Drosophila immune deficiency (IMD) is a death domain protein that activates antibacterial defense and can promote apoptosis.

Georgel P, Naitza S, Kappler C, Ferrandon D, Zachary D, Swimmer C, Kopczynski C, Duyk G, Reichhart JM, Hoffmann JA.

Dev Cell. 2001 Oct;1(4):503-14.

26.

Single nucleotide polymorphism markers for genetic mapping in Drosophila melanogaster.

Hoskins RA, Phan AC, Naeemuddin M, Mapa FA, Ruddy DA, Ryan JJ, Young LM, Wells T, Kopczynski C, Ellis MC.

Genome Res. 2001 Jun;11(6):1100-13.

27.

Drosophila p53 is a structural and functional homolog of the tumor suppressor p53.

Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C, Kopczynski C.

Cell. 2000 Mar 31;101(1):91-101.

28.

Wrapper, a novel member of the Ig superfamily, is expressed by midline glia and is required for them to ensheath commissural axons in Drosophila.

Noordermeer JN, Kopczynski CC, Fetter RD, Bland KS, Chen WY, Goodman CS.

Neuron. 1998 Nov;21(5):991-1001.

29.

A high throughput screen to identify secreted and transmembrane proteins involved in Drosophila embryogenesis.

Kopczynski CC, Noordermeer JN, Serano TL, Chen WY, Pendleton JD, Lewis S, Goodman CS, Rubin GM.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9973-8.

30.

A neural tetraspanin, encoded by late bloomer, that facilitates synapse formation.

Kopczynski CC, Davis GW, Goodman CS.

Science. 1996 Mar 29;271(5257):1867-70.

PMID:
8596956
31.

Asymmetric localization of numb autonomously determines sibling neuron identity in the Drosophila CNS.

Spana EP, Kopczynski C, Goodman CS, Doe CQ.

Development. 1995 Nov;121(11):3489-94.

32.

Genetic analysis of Fasciclin II in Drosophila: defasciculation, refasciculation, and altered fasciculation.

Lin DM, Fetter RD, Kopczynski C, Grenningloh G, Goodman CS.

Neuron. 1994 Nov;13(5):1055-69.

PMID:
7946345
33.
34.

Molecular and genetic intimations of the function of Delta, and EGF-like gene required for ectodermal differentiation in Drosophila.

Kopczynski CC, Fechtel K, Kooh PJ, Shepard SB, Bauer KA, Muskavitch MA.

Mol Reprod Dev. 1990 Sep;27(1):28-36. Review. No abstract available.

PMID:
2271183
36.

Molecular genetics of Delta, a locus required for ectodermal differentiation in Drosophila.

Alton AK, Fechtel K, Kopczynski CC, Shepard SB, Kooh PJ, Muskavitch MA.

Dev Genet. 1989;10(3):261-72.

PMID:
2500289
37.
38.

Cat-2 gene expression. Developmental control of translatable CAT-2 mRNA levels in maize scutellum.

Kopczynski CC, Scandalios JG.

Mol Gen Genet. 1986 Apr;203(1):185-8.

PMID:
2423849

Supplemental Content

Loading ...
Support Center